We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mazor Robotics (MZOR) Receives 25 System Orders in Q3
Read MoreHide Full Article
Israel-based developer of robotic technology and products, Mazor Robotics Ltd. , recently announced that it received 25 surgical guidance system orders during third-quarter 2016. This includes 18 orders for Mazor X, a new platform for spine surgeries using highly automated robotic technologies. The rest consists of four Renaissance systems for the U.S. market and three Renaissance systems for the international market.
The ‘Mazor robotics renaissance guidance system’ (Renaissance System) is a key catalyst for the company. Recently, Mazor Robotics and The Center for Musculoskeletal Disorders announced the first installation of this system in an ambulatory outpatient setting. In this regard, the Renaissance platform is a flagship product of Mazor Robotics that transforms spine surgery from freehand procedures to highly-accurate and state-of-the-art procedures. On a global basis, Mazor Robotics ended the third quarter with installation of 131 systems, of which 79 have been placed in the U.S.
Network expansion has been another major growth driver for the company as it expanded operations in the Myrtle Beach area with Grand Strand Medical Center, installing the Renaissance platform. Notably, this development marked the second installation of this high-end system in the state of South Carolina and the ninth HCA-affiliated facility to buy a Renaissance system.
Of the other developments in the recent past, Mazor Robotics announced the receipt of a massive $20 million equity investment from Medtronic (MDT - Free Report) , a leading medical device company. Notably, in May 2016, Medtronic made an initial investment of $11.9 million in Mazor Robotics and currently owns a 7.2% stake.
Our Take
Mazor Robotics has managed to gain considerable traction in new metropolitan markets and in academic centers within a short span of time.
Internationally, Mazor Robotics continues to work with its distribution partners to expand into the market. On the regulatory front, the company continues to make progress and move closer to approvals in key markets like Japan and South Korea.
Zacks Rank & Key Picks
Currently, Mazor Robotics carries a Zacks Rank #3 (Hold).
Quidel recorded 16.84% in the past one year, higher than the S&P 500’s 6.64%. Over the next five years, the stock is estimated to record earnings growth rate of 20%, higher than the industry average of 14.8%.
NuVasive gained 30.54% over the past one year compared to the S&P 500’s 6.64%. Over the next five years, the stock is expected to see 16.7% earnings growth compared to the industry average of 14.8%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Mazor Robotics (MZOR) Receives 25 System Orders in Q3
Israel-based developer of robotic technology and products, Mazor Robotics Ltd. , recently announced that it received 25 surgical guidance system orders during third-quarter 2016. This includes 18 orders for Mazor X, a new platform for spine surgeries using highly automated robotic technologies. The rest consists of four Renaissance systems for the U.S. market and three Renaissance systems for the international market.
The ‘Mazor robotics renaissance guidance system’ (Renaissance System) is a key catalyst for the company. Recently, Mazor Robotics and The Center for Musculoskeletal Disorders announced the first installation of this system in an ambulatory outpatient setting. In this regard, the Renaissance platform is a flagship product of Mazor Robotics that transforms spine surgery from freehand procedures to highly-accurate and state-of-the-art procedures. On a global basis, Mazor Robotics ended the third quarter with installation of 131 systems, of which 79 have been placed in the U.S.
Network expansion has been another major growth driver for the company as it expanded operations in the Myrtle Beach area with Grand Strand Medical Center, installing the Renaissance platform. Notably, this development marked the second installation of this high-end system in the state of South Carolina and the ninth HCA-affiliated facility to buy a Renaissance system.
MAZOR ROBOTICS Price
MAZOR ROBOTICS Price | MAZOR ROBOTICS Quote
Of the other developments in the recent past, Mazor Robotics announced the receipt of a massive $20 million equity investment from Medtronic (MDT - Free Report) , a leading medical device company. Notably, in May 2016, Medtronic made an initial investment of $11.9 million in Mazor Robotics and currently owns a 7.2% stake.
Our Take
Mazor Robotics has managed to gain considerable traction in new metropolitan markets and in academic centers within a short span of time.
Internationally, Mazor Robotics continues to work with its distribution partners to expand into the market. On the regulatory front, the company continues to make progress and move closer to approvals in key markets like Japan and South Korea.
Zacks Rank & Key Picks
Currently, Mazor Robotics carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the broader medical sector include Quidel Corp. (QDEL - Free Report) and NuVasive, Inc. . Both these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Quidel recorded 16.84% in the past one year, higher than the S&P 500’s 6.64%. Over the next five years, the stock is estimated to record earnings growth rate of 20%, higher than the industry average of 14.8%.
NuVasive gained 30.54% over the past one year compared to the S&P 500’s 6.64%. Over the next five years, the stock is expected to see 16.7% earnings growth compared to the industry average of 14.8%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>